Efficacy and safety of vascular-targeting agents in advanced soft tissue sarcoma: a systematic review and network meta-analysis.

Ther Adv Med Oncol · 2025 · PMC12541171 · PMID 41132824

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

The preliminary phase I/II clinical trials found a clear trend for improving PFS with the addition of olaratumab to chemotherapy, with a 31%–33% reduction in the risk of disease progression. 15 , 16 Tap et al. 16 demonstrated that olaratumab plus doxorubicin significantly improved OS in patients with advanced STS (26.5 vs 14.7 months; HR 0.46; 95% CI 0.30–0.71).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.